🔍

NIVABUPA - Niva Bupa Health

📊 NSE: NIVABUPA 🏢 Finance & Investments 📅 Last Updated: 12/14/2025 10:34

📢 Recent Corporate Announcements

Niva Bupa Allots 2.58 Lakh Equity Shares Under ESOP Scheme 2020

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Mar 2026, 06:36 PM

Niva Bupa Health Insurance Company Limited has announced the allotment of 2,58,200 equity shares on March 05, 2026. These shares were issued to eligible employees who exercised their options under the company's Employee Stock Option Plan 2020 (ESOP Scheme 2020). The new shares carry a face value of ₹10 each and will rank pari-passu with the existing equity shares. This is a routine corporate action that results in a marginal increase in the company's total paid-up share capital.

Allotment of 2,58,200 equity shares to eligible employees under ESOP Scheme 2020
Each share has a face value of ₹10 and ranks equally with existing shares
Allotment date confirmed as March 05, 2026
The issuance follows the exercise of options by eligible grantees

💡 This is a routine administrative update with negligible impact on share value. No specific action is required from investors.

Niva Bupa Receives IRDAI Show Cause Notice and Letter of Advice for Regulatory Violations

🔵 WATCH ⭐ 6/10

REGULATORY 📅 27 Feb 2026, 04:29 PM

Niva Bupa Health Insurance received a Show Cause Notice (SCN) and a Letter of Advice from IRDAI on February 26, 2026, following an inspection conducted in February 2025. The regulatory communication highlights alleged violations of Master Circulars regarding Health Insurance Business, Policyholder Protection, and Corporate Governance. While the company maintains there is no immediate financial or operational impact, it is currently drafting a response to the SCN. Investors should track this development to see if it results in future penalties or stricter regulatory oversight.

IRDAI issued a Show Cause Notice and Letter of Advice on February 26, 2026, regarding business and operational aspects.
Alleged non-compliances relate to Master Circulars on Health Insurance Business, Protection of Policyholders Interest, and Corporate Governance.
The company stated there is no quantifiable financial impact on operations or activities at this stage.
Niva Bupa is in the process of submitting a response to IRDAI and implementing advised compliance measures.

💡 Investors should stay cautious and await the final resolution of the Show Cause Notice to assess potential long-term regulatory risks or penalties. Monitor if these compliance measures lead to increased operational costs or changes in business strategy.

Niva Bupa to Attend Kotak Securities Chasing Growth 2026 Conference on February 24

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Feb 2026, 05:44 PM

Niva Bupa Health Insurance Company Limited has announced its participation in the 'Kotak Securities - Chasing Growth 2026 Conference' scheduled for February 24, 2026. The event will be held in Mumbai and involves interactions with various institutional investors and analysts. This disclosure is a routine compliance filing under Regulation 30 of SEBI (LODR) Regulations. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during the conference.

Participation in Kotak Securities - Chasing Growth 2026 Conference confirmed for Feb 24, 2026.
The meeting is scheduled to take place in Mumbai as a physical conference.
Compliance filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed during the event.

💡 Investors should monitor the company's website or exchange filings after the event for any investor presentations or transcripts that may provide insights into the company's growth outlook. No immediate trading action is required based on this routine scheduling announcement.

Niva Bupa Q3 FY26: 9M PAT Jumps 74% to ₹208 Cr; Retail Market Share Hits 10%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 03 Feb 2026, 05:18 PM

Niva Bupa reported a robust financial performance for the nine months ended December 31, 2025, with Profit After Tax (PAT) increasing 74% YoY to ₹208 crores. The company achieved a retail growth rate of 33%, pushing its retail market share to 10%. Operational efficiency improved as the Expense of Management (EOM) ratio dropped to 35% from 39% YoY, while the combined ratio improved by 50 bps to 102.9%. Despite a ₹20 crore one-off impact from new wage codes, the company maintained a strong solvency ratio of 2.49.

9M PAT surged 74% YoY to ₹208 crores, with Q3 PAT standing at ₹77 crores.
Retail health insurance segment grew by 33% in the 9-month period, with Q3 new business growth at 46%.
Combined Ratio (IFRS) improved by 50 basis points to 102.9% for the 9-month period.
Direct digital channel business witnessed a significant growth of 70% in Q3 FY26.
Solvency ratio remains healthy at 2.49, providing significant cushion for future growth.

💡 Investors should take note of the strong retail growth and improving operating leverage which are driving profitability. The company's ability to gain market share while improving its combined ratio suggests a sustainable growth trajectory.

Niva Bupa Releases Audio Recording of Q3 & 9M FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 29 Jan 2026, 10:38 PM

Niva Bupa Health Insurance Company Limited has officially released the audio recording of its earnings conference call held on January 29, 2026. The call addressed the company's financial and operational performance for the third quarter and the nine-month period ending December 31, 2025. This filing is a routine regulatory requirement under SEBI (LODR) Regulations to ensure transparency for all stakeholders. Investors can access the full recording through the company's dedicated investor relations web page.

Earnings call conducted on January 29, 2026, following the Q3 FY26 results announcement.
Recording covers financial performance for the nine-month period ended December 31, 2025.
Audio file is hosted on the company's official website under the Investor Relations section.
Compliance filing submitted under Regulation 30 of SEBI (LODR) Regulations, 2015.

💡 Investors should listen to the recording to understand management's perspective on loss ratios, premium growth, and the competitive landscape in the health insurance sector.

Niva Bupa Reports 74% YoY Profit Growth to ₹208.3 Cr for 9M FY26

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 07:19 PM

Niva Bupa Health Insurance reported a strong financial performance for the nine months ended December 31, 2025, with net profit surging 74% YoY to ₹20,831 Lakhs. Insurance revenue grew by 35.4% to reach ₹5,71,292 Lakhs, reflecting robust business expansion. Investment income also saw a significant jump of 43% to ₹47,804 Lakhs. While the growth is impressive, the company is currently awaiting IRDAI forbearance for exceeding Expenses of Management (EOM) limits for FY 2024-25.

Net Profit for 9M FY26 increased by 74.3% YoY to ₹20,831 Lakhs from ₹11,952 Lakhs.
Insurance revenue grew 35.4% YoY to ₹5,71,292 Lakhs compared to ₹4,21,786 Lakhs in the previous year.
Investment income rose to ₹47,804 Lakhs, a 43.1% increase over 9M FY25.
Basic Earnings Per Share (EPS) improved significantly to ₹1.13 from ₹0.69 YoY.
The company has applied for IRDAI forbearance regarding exceeding Expenses of Management (EOM) limits for FY 2024-25.

💡 The company demonstrates strong growth momentum in revenue and profitability; investors should maintain a positive outlook while monitoring the IRDAI's decision on management expense limits.

Niva Bupa Authorizes KMPs for Materiality Disclosures Under SEBI Regulations

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 29 Jan 2026, 06:44 PM

Niva Bupa Health Insurance has officially designated three Key Managerial Personnel (KMPs) to determine the materiality of events and information for stock exchange disclosures. This move is in compliance with Regulation 30(5) of the SEBI Listing Regulations. The authorized officials include the Managing Director & CEO, the Executive Director & CFO, and the Company Secretary. This is a standard administrative procedure for listed entities to ensure transparent and timely communication with investors.

Authorization of 3 Key Managerial Personnel (KMPs) for materiality determination under SEBI norms
Designated KMPs include Mr. Krishnan Ramachandran (MD & CEO) and Mr. Vishwanath Mahendra (ED & CFO)
Compliance with Regulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Contact details provided for investor queries via phone (+91-124-6354900) and email (investor@nivabupa.com)

💡 No action is required as this is a routine regulatory filing. Investors should maintain awareness of the designated contact points for future material company updates.

Niva Bupa Appoints Roger Davis as Director and Aparna Sharma as CS & Compliance Officer

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 06:41 PM

Niva Bupa Health Insurance has announced two key leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Director, bringing 40 years of global financial services experience, including roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma has been promoted to Company Secretary and Compliance Officer (KMP) after successfully overseeing the company's IPO execution. These appointments signify a strengthening of corporate governance and strategic oversight for the recently listed entity.

Appointment of Mr. Roger William John Davis as Additional Director with 40 years of global financial experience.
Mr. Davis previously served as Chairman of BUPA, Chairman of Sainsbury’s Bank, and on the Board of Barclays Bank PLC.
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) effective January 29, 2026.
Ms. Sharma brings 15+ years of experience and was instrumental in the company's IPO and SEBI compliance implementation.
The board appointments are subject to member approval within three months.

💡 The addition of a high-caliber global leader from the BUPA group to the board is a positive signal for governance and strategic alignment. Investors should monitor how this leadership transition supports the company's post-IPO growth trajectory.

Niva Bupa Appoints Roger Davis as Non-Executive Director and Aparna Sharma as Company Secretary

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 06:39 PM

Niva Bupa Health Insurance has announced two significant leadership appointments effective January 29, 2026. Mr. Roger William John Davis joins as an Additional Non-Executive Director, bringing 40 years of global financial services experience, including former roles as Chairman of BUPA and Sainsbury’s Bank. Additionally, Ms. Aparna Sharma, who has over 15 years of experience in corporate governance and was instrumental in the company's IPO, has been appointed as Company Secretary and Compliance Officer. These appointments are expected to strengthen the company's governance framework and strategic oversight.

Appointment of Mr. Roger William John Davis as Additional Non-Executive Director effective January 29, 2026
Mr. Davis brings 40 years of experience, having served as Chairman of BUPA and on the Board of Barclays Bank PLC
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) with 15+ years of experience
Mr. Davis previously held leadership roles including MD of India for Jardine Fleming and CEO of BZW Asia Pacific
Director appointment is subject to shareholder approval within three months from the date of appointment

💡 The addition of a high-profile international director like Roger Davis is a positive signal for the company's corporate governance and global strategic alignment. Investors should maintain a positive outlook on the stock as the company strengthens its leadership post-listing.

Niva Bupa Appoints Former Bupa Chairman Roger Davis as Director and New Company Secretary

🟢 POSITIVE ⭐ 7/10

MANAGEMENT 📅 29 Jan 2026, 06:36 PM

Niva Bupa Health Insurance has announced the appointment of Mr. Roger William John Davis as a Non-Executive Director, effective January 29, 2026. Mr. Davis brings 40 years of global financial services experience, including roles as Chairman of Bupa and Managing Director of India for Jardine Fleming. Simultaneously, the company appointed Ms. Aparna Sharma as Company Secretary and Compliance Officer, leveraging her 15 years of experience in corporate governance and IPO execution. These leadership additions are aimed at strengthening the company's governance framework and strategic oversight.

Appointment of Mr. Roger William John Davis as Non-Executive Director with 40 years of global financial services experience
Mr. Davis previously served as Chairman of Bupa, Chairman of Sainsbury’s Bank, and on the Board of Barclays Bank PLC
Ms. Aparna Sharma appointed as Company Secretary and Compliance Officer (KMP) with 15+ years of multifaceted experience
Appointments are effective from January 29, 2026, following a Board meeting held on the same day
The director appointment is subject to shareholder approval within three months

💡 The inclusion of a high-caliber professional like the former Bupa Chairman on the board is a positive signal for governance and strategic alignment. Investors should view this as a strengthening of the leadership team following the company's recent listing.

Niva Bupa 9M FY26 PAT Jumps 74% to ₹208 Cr; Retail Health Market Share Hits 10%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 06:09 PM

Niva Bupa reported a robust performance for the nine months ended December 31, 2025, with IFRS Profit After Tax (PAT) surging 74.3% YoY to ₹208.3 crore. Gross Written Premium (GWP) grew by 25.9% to ₹6,309.4 crore, significantly outperforming the industry's health segment growth of 15.6%. The company's retail health market share improved to 10.0%, while the Combined Insurance Service Ratio (CISR) showed efficiency gains, narrowing to 102.9% from 103.4% YoY. High renewal rates of 91.8% in the retail health indemnity segment further underscore strong customer retention.

9M FY26 IFRS PAT increased by 74.3% YoY to ₹208.3 crore from ₹119.5 crore.
Gross Written Premium (GWP) grew 25.9% YoY to ₹6,309.4 crore, led by 32.9% growth in Retail Health.
Retail Health market share expanded to 10.0% in 9M FY26 compared to 9.6% in 9M FY25.
Combined Insurance Service Ratio (CISR) improved to 102.9% from 103.4% YoY, reflecting better operational efficiency.
Individual agent network grew to 224,810, with 15,000 agents added in Q3 FY26 alone.

💡 Investors should view the strong growth in the high-margin retail health segment and the significant jump in profitability as positive indicators. The company's ability to outpace industry growth while improving its combined ratio suggests a sustainable path toward higher return on equity.

Niva Bupa Q3 FY26: 9M PAT Surges 74% to ₹208 Cr; Retail Market Share Hits 10.2%

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 06:06 PM

Niva Bupa reported a robust financial performance for Q3 FY26, with 9M FY26 Profit After Tax (PAT) surging over 74% to ₹208 crore. The company's Gross Written Premium (GWP) on a reported basis grew 55% YoY in Q3 to ₹2,231 crore, while retail health market share expanded to 10.2%. Operational efficiency improved as the Combined Insurance Service Ratio for 9M FY26 decreased by 0.51 percentage points. With 24.5 million lives insured and a 94.1% claim settlement ratio, the company is demonstrating strong scaling and customer retention.

9M FY26 Profit After Tax (PAT) reached ₹208 crore, a 74% year-on-year surge.
Q3 FY26 Gross Written Premium (GWP) grew 55% YoY to ₹2,231 crore on a reported basis.
Retail health market share increased by 1.4 percentage points YoY to reach 10.2% in Q3 FY26.
Claim Settlement Ratio remained strong at 94.1% for Q3 FY26 with 24.5 million lives insured.
Combined Insurance Service Ratio for 9M FY26 improved by 0.51 percentage points YoY.

💡 Investors should consider the strong growth in retail market share and the significant PAT surge as positive indicators of scaling profitability. Monitor the sustainability of premium growth and the combined ratio in future quarters to assess long-term efficiency.

Niva Bupa Q3 FY26: Gross Premium Jumps 55% YoY; Reports Net Loss of ₹87.6 Crore

🔴 NEGATIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 05:57 PM

Niva Bupa reported a robust 55% YoY growth in Gross Written Premium at ₹2,231.27 crore for Q3 FY26. Despite the top-line growth, the company swung to a net loss of ₹87.64 crore from a profit of ₹13.24 crore in the previous year's quarter. This loss was driven by a significant increase in the incurred claim ratio, which rose to 72.30% from 65.14%. For the nine-month period ended December 2025, the company recorded a total net loss of ₹214.35 crore.

Gross Premiums Written increased by 54.7% YoY to ₹2,231.27 crore in Q3 FY26.
Net Loss for the quarter stood at ₹87.64 crore compared to a profit of ₹13.24 crore in Q3 FY25.
Incurred Claim Ratio worsened to 72.30% from 65.14% in the corresponding quarter last year.
Solvency Ratio remains healthy at 2.49, though it has declined from 3.03 a year ago.
Combined Ratio remains elevated at 108.19%, indicating continued underwriting losses.

💡 Investors should monitor the rising claim ratios and underwriting losses despite strong premium growth. The company's ability to turn profitable depends on managing its combined ratio and obtaining regulatory forbearance for management expenses.

Niva Bupa Schedules Q3 & 9M FY26 Earnings Conference Call for January 29, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 21 Jan 2026, 06:26 PM

Niva Bupa Health Insurance has announced its earnings conference call scheduled for January 29, 2026, at 6:30 PM IST. The management will discuss the financial results for the quarter and nine-month period ending December 31, 2025. The call will feature top leadership, including the Managing Director and the Chief Financial Officer. This is a standard regulatory filing to inform shareholders about the upcoming performance review and management outlook.

Conference call set for January 29, 2026, at 18:30 IST to discuss Q3FY26 results.
Top management including MD & CEO Krishnan Ramachandran and CFO Vishwanath Mahendra will be present.
The call covers performance for the nine-month period ending December 31, 2025.
Universal access numbers (+91 22 6280 1144) and international toll-free lines are provided for global investors.

💡 Investors should monitor the upcoming earnings call for insights into the company's premium growth and claims ratio trends. No immediate action is required based on this scheduling announcement.

Niva Bupa Submits SEBI Regulation 74(5) Compliance Certificate for Q3 FY26

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Jan 2026, 05:30 PM

Niva Bupa Health Insurance Company Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The report, issued by KFin Technologies Limited, covers the quarter ended December 31, 2025. The registrar confirmed that no dematerialization requests were received during this period. This is attributed to the fact that all shares of the company are already held in electronic form.

Compliance certificate submitted for the quarter ended December 31, 2025
KFin Technologies Limited confirmed zero demat requests were processed
The company maintains 100% of its shares in dematerialized mode
Filing is a standard regulatory requirement for listed entities in India

💡 No action is required from investors as this is a routine administrative filing confirming existing shareholding structures.

View All NIVABUPA Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Gross Written Premium (GWP) grew by 20.59% YoY to reach INR 6,762.23 Cr in FY25. The bancassurance channel specifically grew by 24% YoY, contributing INR 1,359 Cr in premiums. Growth without the '1/N' accounting impact was reported at 32.1% for FY25.

Geographic Revenue Split

As of 6MFY24, revenue was distributed across Maharashtra (15.6%), Uttar Pradesh (10.9%), Delhi (9.5%), Karnataka (9.3%), Haryana (7.6%), Telangana (6.4%), and Gujarat (5.4%).

Profitability Margins

Profit After Tax (PAT) surged 160.8% YoY to INR 213.52 Cr in FY25 from INR 81.85 Cr in FY24. The Return on Net Worth (RONW) improved significantly from 3.99% to 6.98% during the same period. The Net Earnings Ratio stood at 3.98% in FY25 compared to 1.85% in FY24.

EBITDA Margin

Operating Profit Ratio was 3.68% in FY25, a decrease from 4.93% in FY24, primarily due to the transition to 1/n basis premium recognition. The combined operating ratio stood at 105.10% in FY25, slightly improved from 105.15% in FY24.

Capital Expenditure

The company significantly expanded its capital base by raising INR 800 Cr from investors including Temasek and Motilal Oswal, followed by an IPO that brought the paid-up share capital to INR 1,827.03 Cr as of March 31, 2025.

Credit Rating & Borrowing

CARE Ratings assigned a 'CARE A+; Stable' rating to the company's INR 250 Cr subordinate debt, upgraded from 'CARE A; Stable' due to a substantial increase in the capital base and a solvency ratio of 2.5x.

⚙️ Operational Drivers

Raw Materials

As an insurance provider, primary 'input' costs are Claims Incurred (Net) at INR 2,996.52 Cr (44.3% of GWP) and Commission Paid (Net) at INR 1,064.57 Cr (15.7% of GWP).

Import Sources

Not applicable for insurance services; sourcing relates to domestic distribution and healthcare provider networks across India.

Key Suppliers

Not applicable; the company partners with healthcare providers and distributors. It added 7 new bancassurance partners in FY25 to expand its distribution reach.

Capacity Expansion

The company expanded its physical footprint to 201 offices as of September 2023, up from 161 offices in March 2022. The investment book expanded to INR 8,175 Cr in FY25 from INR 5,458 Cr in FY24.

Raw Material Costs

Claims incurred (Net) rose 33% YoY to INR 2,996.52 Cr in FY25. The loss ratio increased to 61.2% in FY25 from 59.0% in FY24, impacting the combined ratio.

Manufacturing Efficiency

The Expense of Management (EOM) to Net Written Premium ratio was 49.39% in FY25. For H1 FY26, the EOM ratio was 36.3%, slightly above the regulatory limit of 35.8%.

Logistics & Distribution

Distribution is multi-channel; commission expenses increased to INR 1,064.57 Cr in FY25 from INR 748.18 Cr in FY24 to support a 20.59% growth in GWP.

📈 Strategic Growth

Expected Growth Rate

20.59%

Growth Strategy

Growth is driven by a multi-channel distribution strategy with a heavy emphasis on digital sales and bancassurance. The company added 7 new bank partners and is leveraging its association with Bupa Singapore Holdings (56% stake) for brand and strategic oversight.

Products & Services

Health insurance policies, including retail health, group health, and specialized health insurance products.

Brand Portfolio

Niva Bupa (formerly Max Bupa).

New Products/Services

Not disclosed in specific percentages, but the company focuses on diversified health insurance products across retail and group segments.

Market Expansion

Targeting increased market share in the Standalone Health Insurance (SAHI) segment, which improved to 17.59% in FY25 from 16.93% in FY24.

Market Share & Ranking

Overall health insurance market share increased to 5.31% in FY25 from 4.81% in FY24. Ranked as a leading Standalone Health Insurer (SAHI).

Strategic Alliances

Subsidiary of Bupa Singapore Holdings Pte. Limited (56% stake). Strategic investors include Temasek, Motilal Oswal, SBI Life, and Paragon.

🌍 External Factors

Industry Trends

The health insurance industry grew at 9.07% in FY25, while NBHI outpaced this at 20.59%. Trends include a shift toward digital distribution and regulatory shifts like the 1/n accounting method.

Competitive Landscape

Competes with other SAHIs (Standalone Health Insurers) and general insurance companies. NBHI holds a 17.59% share among SAHIs.

Competitive Moat

Moat is built on strong parentage (Bupa), a diversified distribution network (201 offices + bancassurance), and a high solvency ratio (2.5x) which allows for aggressive growth compared to peers.

Macro Economic Sensitivity

Highly sensitive to healthcare inflation and regulatory changes by IRDAI. Investment income (INR 479.83 Cr) is sensitive to interest rate cycles.

Consumer Behavior

Increasing demand for retail health insurance and digital-first purchase journeys.

Geopolitical Risks

Low direct impact as a domestic health insurer, though global parentage (Bupa UK) provides strategic stability.

⚖️ Regulatory & Governance

Industry Regulations

Subject to IRDAI regulations, including the 1/n accounting method for GWP and a 35% Expense of Management (EOM) limit. The company is currently at 36.3% EOM and aims to align by FY26 end.

Environmental Compliance

Exposure to environmental risks is low; the company has internal risk assessment mechanisms for ESG.

Taxation Policy Impact

Not disclosed as a specific percentage, but PAT was reported after tax provisions at INR 213.52 Cr.

Legal Contingencies

The company received a letter from the Insurance Regulatory and Development Authority of India (IRDAI) on November 12, 2025, regarding regulatory matters; specific case values were not disclosed.

⚠️ Risk Analysis

Key Uncertainties

The primary uncertainty is the loss ratio, which rose to 61.2% in FY25. Regulatory compliance regarding EOM limits (currently 50 bps above limit) poses a compliance risk.